Concert Pharmaceuticals, Inc. CNCE
8.37 0.00 (+0.00%)
At closeMar 3, 2023, 4:00 PM EST
8.35 Day range 8.55
52-week range unavailable
- Open
- 8.38
- Previous close
- 8.37
- Day's range
- 8.35 – 8.55
- Analysts
- Buy
- Price target
- 13.00 (+55.3%)
- Earnings date
- Mar 9, 2023
No chart data for this range yet.
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: buy
Buy
Price target (mean) 13.00 +55.3% upside
Now 8.37
- Target (low)
- 9.00
- Target (mean)
- 13.00
- Target (high)
- 17.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 9, 2023
Expected Mar 9, 2023. Consensus EPS estimate -0.63.
Financials — quick view
CNCE Revenue — quarterly 8.00K
CNCE Net income — quarterly -28.90M
CNCE EPS — quarterly -0.58
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 9, 2023 | Dec 1, 2022 | -0.59 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | -0.59 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.90 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.93 | — | — | — |
| Mar 3, 2022 | Dec 1, 2021 | -0.76 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -0.76 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 19, 2023 | JonesTrading | down | Buy | Hold |
| Sep 12, 2022 | Truist Securities | main | — | Buy |
| Aug 24, 2022 | JonesTrading | init | — | Buy |
| Oct 4, 2021 | Mizuho | main | — | Buy |
| Feb 1, 2021 | Truist Securities | main | — | Buy |
| Dec 15, 2020 | Berenberg | init | — | Buy |
News
Concert Pharmaceuticals: Negative Spread But Interesting CVR 
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata 
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata 
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders 
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders 
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations 
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer 
Why Concert Pharmaceuticals Stock Rocketed Higher This Week 
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE 
SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.
Your note
Sign in to keep a note on CNCE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALDRICH RICHARD H | Director | Stock Award(Grant) | Jun 8, 2022 | 613,377 |
| AUCHINCLOSS THOMAS G JR | Director | Stock Award(Grant) | Jun 8, 2022 | 34,025 |
| BECKER MARC A | Chief Financial Officer | Sale | Feb 14, 2023 | 123,863 |
| CASSELLA JAMES V | Officer | Sale | Feb 14, 2023 | 173,061 |
| HUTT PETER BARTON | Director | Sale | Oct 13, 2022 | 29,488 |
| JAEGER WILFRED E | Director | Stock Award(Grant) | Jun 8, 2022 | 21,525 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kynam Capital Management, LP | 7.11% | 4,420,349 | 25.81M | Dec 30, 2022 |
| BVF Inc. | 5.83% | 3,629,000 | 21.19M | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 3.07% | 1,910,984 | 11.16M | Dec 30, 2022 |
| Nantahala Capital Management, LLC | 2.78% | 1,732,388 | 10.12M | Dec 30, 2022 |
| Millennium Management Llc | 2.32% | 1,441,735 | 8.42M | Dec 30, 2022 |
| Citadel Advisors Llc | 2.24% | 1,391,302 | 8.13M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.85% | 1,153,883 | 7.73M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.97% | 604,519 | 4.05M | Sep 29, 2022 |
| iShares NASDAQ Biotechnology ETF | 0.61% | 378,364 | 2.21M | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.34% | 211,131 | 1.02M | Nov 29, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 138,100 | 925.27K | Sep 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.22% | 136,040 | 794.47K | Dec 30, 2022 |